Artelo Biosciences (ARTL) Convertible Debt (2025)

Artelo Biosciences (ARTL) posted quarterly Convertible Debt of $609000.0 for Q4 2025, down 30.4% quarter-over-quarter from $875000.0 in Q3 2025.

Artelo Biosciences (ARTL) Convertible Debt (2025) Analysis & Trends

Artelo Biosciences (ARTL) has reported Convertible Debt for 1 consecutive years, with $609000.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Convertible Debt changed N/A year-over-year to $609000.0; the TTM figure through Dec 2025 stood at $609000.0 (changed N/A YoY), while the FY2025 annual figure was $609000.0, changed N/A from the prior year.
Convertible Debt retreated to $609000.0 in Q4 2025 per ARTL's latest filing, from $875000.0 in the prior quarter.
Across five years, Convertible Debt topped out at $875000.0 in Q3 2025 and bottomed at $609000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Artelo Biosciences	111,698.23	-488,301.77	-

Download Data